Literature DB >> 24607918

Prediction of preeclampsia by placental protein 13 and background risk factors and its prevention by aspirin.

Hamutal Meiri, Marei Sammar, Ayelet Herzog, Yael-Inna Grimpel, Galina Fihaman, Aliza Cohen, Vered Kivity, Adi Sharabi-Nov, Ron Gonen.   

Abstract

AIM: Evaluation of placental protein 13 (PP13) and risk factors (RFs) as markers for predicting preeclampsia (PE) and use of aspirin for PE prevention.
MATERIALS AND METHODS: First-trimester pregnancy screening was based on having PP13 level ≤0.4 multiple of the median (MoM) and/or at least one major risk factor (RF) for PE. Management was by routine care or combined with daily treatment with 75 mg aspirin between 14 and 35 weeks of gestation.
RESULTS: Of 820 deliveries, 63 women developed PE (7.7%). Median PP13 levels was 0.2MoM in the PE group compared with 0.83MoM among unaffected and 1.0MoM in unaffected not treated with aspirin (P<0.0001). Low PP13 was a better predictor for PE versus major RFs, particularly for young nuliparous. Combining low PP13 with RFs increased prediction accuracy. Mean arterial pressure (not included in the initial prediction), could add to prediction accuracy when combined with low PP13 and RFs. PE prevention by aspirin was most effective when the risk was determined by low PP13 alone, less effective for combining low PP13 with RFs, and ineffective when determined by RFs alone.
CONCLUSION: When PE risk is determined by low first trimester PP13 or by combined low PP13 and RFs, prevention with aspirin is warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24607918     DOI: 10.1515/jpm-2013-0298

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  10 in total

Review 1.  Extracellular Vesicles and Preeclampsia: Current Knowledge and Future Research Directions.

Authors:  Carlos Palma; Jessica Jellins; Andrew Lai; Alexis Salas; America Campos; Shayna Sharma; Gregory Duncombe; Jon Hyett; Carlos Salomon
Journal:  Subcell Biochem       Date:  2021

2.  Predictive performance of first trimester serum galectin-13/PP-13 in preeclampsia screening: A systematic review and meta-analysis.

Authors:  Ingrid-Andrada Vasilache; Alexandru Carauleanu; Demetra Socolov; Roxana Matasariu; Ioana Pavaleanu; Dragos Nemescu
Journal:  Exp Ther Med       Date:  2022-04-05       Impact factor: 2.751

Review 3.  Recent advances in the diagnosis and management of pre-eclampsia.

Authors:  Kate Duhig; Brooke Vandermolen; Andrew Shennan
Journal:  F1000Res       Date:  2018-02-28

4.  Correlation between CHA2DS2-VASc Score and Glaucoma Treatment and Prognosis.

Authors:  Yoav Y Pikkel; Daniel Krebs; Vadim Igal; Adi Sharabi-Nov; Irena Epstein; Joseph Pikkel
Journal:  J Ophthalmol       Date:  2018-01-31       Impact factor: 1.909

Review 5.  Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function.

Authors:  Hamutal Meiri; George Osol; Irene Cetin; Sveinbjörn Gizurarson; Berthold Huppertz
Journal:  Comput Struct Biotechnol J       Date:  2017-09-22       Impact factor: 7.271

6.  Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response.

Authors:  Andrea Balogh; Eszter Toth; Roberto Romero; Katalin Parej; Diana Csala; Nikolett L Szenasi; Istvan Hajdu; Kata Juhasz; Arpad F Kovacs; Hamutal Meiri; Petronella Hupuczi; Adi L Tarca; Sonia S Hassan; Offer Erez; Peter Zavodszky; Janos Matko; Zoltan Papp; Simona W Rossi; Sinuhe Hahn; Eva Pallinger; Nandor Gabor Than
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 7.  Combined Screening for Early Detection of Pre-Eclampsia.

Authors:  Hee Jin Park; Sung Shin Shim; Dong Hyun Cha
Journal:  Int J Mol Sci       Date:  2015-08-04       Impact factor: 5.923

Review 8.  Placental Protein 13 (PP13) - A Placental Immunoregulatory Galectin Protecting Pregnancy.

Authors:  Nándor Gábor Than; Andrea Balogh; Roberto Romero; Eva Kárpáti; Offer Erez; András Szilágyi; Ilona Kovalszky; Marei Sammar; Sveinbjorn Gizurarson; János Matkó; Péter Závodszky; Zoltán Papp; Hamutal Meiri
Journal:  Front Immunol       Date:  2014-08-20       Impact factor: 7.561

Review 9.  Recent advances in the diagnosis and management of pre-eclampsia.

Authors:  Kate E Duhig; Andrew H Shennan
Journal:  F1000Prime Rep       Date:  2015-02-03

Review 10.  Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during Pregnancy.

Authors:  Suchismita Dutta; Sathish Kumar; Jon Hyett; Carlos Salomon
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.